Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Overview of attention for article published in Journal of Clinical Oncology, May 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 4 Google+ posts from 4 users.

Melanoma treatment even in late stage. (T-VEC) is a herpes simplex virus type 1–derived oncolytic im... Melanoma treatment even…

Melanoma treatment even in late stage. (T-VEC) is a herpes simplex virus type 1–derived oncolytic im... Melanoma treatment even…

And this is good news. And this is good news. Talimogene Laherparepvec Improves Durable Response Rate in Patients With…

Melanoma treatment even in late stage. (T-VEC) is a herpes simplex virus type 1–derived oncolytic im... Melanoma treatment even…

This page shows the most recent Google+ posts that mention this research output. Click here to find out how to access more activity.